维生素K缺乏或拮抗剂II、甲胎蛋白、D-二聚体联合检测对乙型

StephenW

维生素K缺乏或拮抗剂II、甲胎蛋白、D-二聚体联合检测对乙型肝炎病毒相关肝细胞癌的诊断价值
      

    全文
    指标
    获得许可
    引用这篇文章

作者 彭 F, 袁 H, Zhou YF, Wu SX, Long ZY, Peng YM

2022 年 2 月 14 日收到

2022 年 6 月 15 日接受出版

2022 年 6 月 23 日出版第 2022 卷：15 页 5763-5773

DOI https://doi.org/10.2147/IJGM.S362359

检查抄袭 是

通过单一匿名同行评审进行评审

同行评审意见 2

批准出版的编辑：Scott Fraser 博士
下载文章 [PDF]


方鹏,1 郝源,1 周一峰,2 吴思贤,1 甄一龙,1 彭亚萌1

1湖南师范大学第一附属医院湖南省人民医院临床检验科,长沙 410005; 2湖南师范大学第一附属医院湖南省人民医院手术室,长沙 410005

通讯作者: 湖南师范大学第一附属医院湖南省人民医院临床检验科袁昊, 中华人民共和国长沙, 410005, 电话+8613677366519, 邮箱[email protected]

目的：探讨维生素K缺乏或拮抗剂II（PIVKA-II）、甲胎蛋白（AFP）和D-二聚体（D-D）联合检测在乙型肝炎病毒（HBV）中的临床诊断价值。相关的肝细胞癌（HCC）。
材料和方法：我们分析了 291 名受试者的 PIVKA-II、AFP 和 D-D 水平，包括肝硬化 (LC) 患者 (n = 143) 和 HCC 患者 (n = 148)。受试者工作特征（ROC）曲线用于分析和比较三种生物标志物单独和组合对HBV相关HCC的临床诊断价值。
结果： PIVKA-II、AFP 和 D-D 水平与 HCC 患者的肿瘤大小呈正相关。早期 HCC、晚期 HCC、HBV DNA+ HCC 和 HBV DNA- HCC 患者 PIVKA-II 和 AFP 水平高于 LC 患者，而 D-D 水平较低。在早期HCC、晚期HCC、HBV DNA+HCC和HBV DNA-HCC患者中，联合检测的曲线下面积大于单指标检测的曲线下面积。
结论：D-D可能是诊断HBV相关HCC的有用生物标志物。 PIVKA-II、AFP、D-D联合检测对不同类型HCC的诊断价值优于单个生物标志物的检测。

关键词：PIVKA-II，甲胎蛋白，D-二聚体，生物标志物，肝细胞癌，乙型肝炎病毒

StephenW

Diagnostic Value of Combined Detection via Protein Induced by Vitamin K Absence or Antagonist II, Alpha-Fetoprotein, and D-Dimer in Hepatitis B Virus-Related Hepatocellular Carcinoma
      

    Fulltext
    Metrics
    Get Permission
    Cite this article

Authors Peng F, Yuan H , Zhou YF, Wu SX, Long ZY, Peng YM

Received 14 February 2022

Accepted for publication 15 June 2022

Published 23 June 2022 Volume 2022:15 Pages 5763—5773

DOI https://doi.org/10.2147/IJGM.S362359

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser
Download Article [PDF]


Fang Peng,1 Hao Yuan,1 Yi-Feng Zhou,2 Si-Xian Wu,1 Zhen-Yi Long,1 Ya-Meng Peng1

1Department of Clinical Laboratory, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 410005, People’s Republic of China; 2Operating Room, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 410005, People’s Republic of China

Correspondence: Hao Yuan, Department of Clinical Laboratory, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 410005, People’s Republic of China, Tel +8613677366519, Email [email protected]

Purpose: We aimed to explore the clinical diagnostic value of combined detection via protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), and D-dimer (D-D) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
Materials and Methods: We analyzed PIVKA-II, AFP, and D-D levels in 291 subjects comprising liver cirrhosis (LC) patients (n = 143) and HCC patients (n = 148). Receiver operating characteristic (ROC) curves were used to analyze and compare the clinical diagnostic value of the three biomarkers for HBV-related HCC alone and in combination.
Results: The levels of PIVKA-II, AFP, and D-D were positively correlated with tumor size in HCC patients. The levels of PIVKA-II and AFP in early-stage HCC, advanced HCC, HBV DNA+ HCC, and HBV DNA- HCC patients were higher than those in LC patients, while the levels of D-D were lower. The area under the curve for combined detection was greater than that for single-index detection in early-stage HCC, advanced HCC, HBV DNA+ HCC, and HBV DNA- HCC patients.
Conclusion: D-D may be a useful biomarker for the diagnosis of HBV-related HCC. The combined detection of PIVKA-II, AFP, and D-D had better diagnostic value for different types of HCC than the detection of individual biomarkers.

Keywords: PIVKA-II, alpha-fetoprotein, D-dimer, biomarker, hepatocellular carcinoma, hepatitis B virus

StephenW

https://www.dovepress.com/diagno ... lltext-article-IJGM